| 2026-08-24 | Warning letter | FDA warning letter to NuScience Peptides LLC: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-08-24 | Warning letter | FDA warning letter to Peak Performance Peptides: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-08-24 | Warning letter | FDA warning letter to Peptide Partners LLC: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-08-24 | Warning letter | FDA warning letter to Royal Peptides LLC: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-08-24 | Warning letter | FDA warning letter to TXP Innovations LLC dba Tex Peptides: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-06-05 | Trial | New trial registered: Pre-approval Expanded Access of Retatrutide (LY3437943) | Trial register ClinicalTrials.gov |
| 2026-04-16 | Action | Ohio Board of Pharmacy: board | Regulator Ohio Board of Pharmacy |
| 2026-03-31 | Warning letter | FDA warning letter to Gram Peptides: Unapproved New Drugs Sold Over the Internet | Regulator FDA warning letters |
| 2026-03-31 | Warning letter | FDA warning letter to Lovega LLC dba Pink Pony Peptides: Unapproved New Drugs Sold Over the Internet | Regulator FDA warning letters |
| 2026-03-31 | Warning letter | FDA warning letter to Mile High Compounds LLC: Unapproved New Drugs Sold Over the Internet | Regulator FDA warning letters |
| 2026-03-31 | Warning letter | FDA warning letter to Prime Sciences: Unapproved New Drugs Sold Over the Internet | Regulator FDA warning letters |
| 2026-03-12 | Trial | New trial registered: Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight | Trial register ClinicalTrials.gov |
| 2026-01-22 | Trial | New trial registered: A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Trial register ClinicalTrials.gov |
| 2026-01-20 | Warning letter | FDA warning letter to GenoGenix LLC: Compounding Pharmacy/Adulterated Drug Products | Regulator FDA warning letters |
| 2025-12-08 | Warning letter | FDA warning letter to Darmerica, LLC: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded | Regulator FDA warning letters |
| 2025-11-18 | Trial | New trial registered: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Trial register ClinicalTrials.gov |
| 2025-10-15 | Recall | FDA recall, Class II: GenoGenix LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2025-09-10 | Trial | New trial registered: A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Trial register ClinicalTrials.gov |
| 2025-09-09 | Warning letter | FDA warning letter to Amazing Meds: Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Regulator FDA warning letters |
| 2025-09-09 | Warning letter | FDA warning letter to ASN-LABS: Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Regulator FDA warning letters |
| 2025-09-09 | Warning letter | FDA warning letter to EA WORKS Limited Liability Company dba Trust Labs: Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Te | Regulator FDA warning letters |
| 2025-09-09 | Warning letter | FDA warning letter to GenLabMeds: Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Regulator FDA warning letters |
| 2025-09-09 | Warning letter | FDA warning letter to GLP-1 Solution: Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Regulator FDA warning letters |
| 2025-09-09 | Warning letter | FDA warning letter to MedClub by Dr. Jenn: Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Regulator FDA warning letters |
| 2025-06-24 | Trial | New trial registered: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Trial register ClinicalTrials.gov |
| 2025-05-21 | Trial | New trial registered: A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Trial register ClinicalTrials.gov |
| 2025-05-21 | Trial | New trial registered: A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia | Trial register ClinicalTrials.gov |
| 2025-03-05 | Trial | New trial registered: A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Trial register ClinicalTrials.gov |
| 2025-02-05 | Trial | New trial registered: To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants | Trial register ClinicalTrials.gov |
| 2024-12-10 | Warning letter | FDA warning letter to Prime Vitality, Inc. dba Prime Peptides: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2024-12-10 | Warning letter | FDA warning letter to Summit Research Peptides: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2024-12-10 | Warning letter | FDA warning letter to Swisschems: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2024-12-10 | Warning letter | FDA warning letter to Xcel Research LLC: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2024-10-28 | Trial | New trial registered: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Trial register ClinicalTrials.gov |
| 2024-04-25 | Trial | New trial registered: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Trial register ClinicalTrials.gov |
| 2024-04-09 | Trial | New trial registered: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | Trial register ClinicalTrials.gov |
| 2024-03-11 | Trial | New trial registered: A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 | Trial register ClinicalTrials.gov |
| 2024-03-07 | Trial | New trial registered: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic C | Trial register ClinicalTrials.gov |
| 2024-02-15 | Trial | New trial registered: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Wi | Trial register ClinicalTrials.gov |
| 2023-09-13 | Results | Results posted: A Study of LY3437943 in Participants Who Have Obesity or Are Overweight | Trial register ClinicalTrials.gov |
| 2023-09-11 | Trial | New trial registered: A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese | Trial register ClinicalTrials.gov |
| 2023-08-16 | Trial | New trial registered: A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices | Trial register ClinicalTrials.gov |
| 2023-07-17 | Trial | New trial registered: A Study of LY3437943 in Healthy Participants With a High Body Mass Index | Trial register ClinicalTrials.gov |
| 2023-07-07 | Trial | New trial registered: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Di | Trial register ClinicalTrials.gov |
| 2023-07-05 | Trial | New trial registered: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | Trial register ClinicalTrials.gov |
| 2023-07-03 | Results | Results posted: A Study of LY3437943 in Participants With Type 2 Diabetes | Trial register ClinicalTrials.gov |
| 2023-07-03 | Trial | New trial registered: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Trial register ClinicalTrials.gov |
| 2023-07-03 | Trial | New trial registered: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Trial register ClinicalTrials.gov |
| 2023-06-15 | Trial | New trial registered: A Study of LY3437943 in Participants With Impaired and Normal Liver Function | Trial register ClinicalTrials.gov |
| 2023-05-31 | Trial | New trial registered: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Trial register ClinicalTrials.gov |
| 2022-11-03 | Trial | New trial registered: A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function | Trial register ClinicalTrials.gov |
| 2022-09-16 | Trial | New trial registered: A Study of LY3437943 in Chinese Participants With Obesity Or Overweight | Trial register ClinicalTrials.gov |
| 2022-07-01 | Trial | New trial registered: A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | Trial register ClinicalTrials.gov |
| 2021-05-10 | Trial | New trial registered: A Study of LY3437943 in Participants Who Have Obesity or Are Overweight | Trial register ClinicalTrials.gov |
| 2021-04-30 | Trial | New trial registered: A Study of LY3437943 in Participants With Type 2 Diabetes | Trial register ClinicalTrials.gov |
| 2021-03-29 | Trial | New trial registered: A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) | Trial register ClinicalTrials.gov |
| 2019-10-29 | Trial | New trial registered: A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | Trial register ClinicalTrials.gov |
| 2019-02-13 | Trial | New trial registered: A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants | Trial register ClinicalTrials.gov |